Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report released on Friday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Down 54.8 %

Eagle Pharmaceuticals stock opened at $0.90 on Friday. The firm has a 50 day moving average price of $4.19 and a 200-day moving average price of $4.53. Eagle Pharmaceuticals has a twelve month low of $0.75 and a twelve month high of $14.78. The company has a market capitalization of $11.69 million, a P/E ratio of 0.76 and a beta of 0.51.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Eagle Pharmaceuticals by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock valued at $3,358,000 after buying an additional 2,630 shares in the last quarter. Headlands Technologies LLC boosted its holdings in shares of Eagle Pharmaceuticals by 75.7% in the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after acquiring an additional 2,861 shares during the period. Mackenzie Financial Corp purchased a new position in shares of Eagle Pharmaceuticals in the second quarter valued at $60,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter valued at $65,000. Finally, Fidelis Capital Partners LLC bought a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter valued at $71,000. Institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.